PharMerica Rating Reiterated by ISI Group (PMC)
PharMerica (NYSE:PMC) traded down 0.78% on Wednesday, hitting $29.19. The stock had a trading volume of 164,050 shares. PharMerica has a 52-week low of $11.84 and a 52-week high of $30.48. The stock has a 50-day moving average of $28.31 and a 200-day moving average of $25.7. The company has a market cap of $875.5 million and a price-to-earnings ratio of 66.71.
PharMerica (NYSE:PMC) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.04. The company had revenue of $452.20 million for the quarter, compared to the consensus estimate of $417.76 million. During the same quarter in the previous year, the company posted $0.46 earnings per share. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. Analysts expect that PharMerica will post $1.49 EPS for the current fiscal year.
A number of other firms have also recently commented on PMC. Analysts at KeyCorp reiterated a “buy” rating on shares of PharMerica in a research note on Monday, June 9th. They now have a $33.00 price target on the stock, up previously from $31.00. Separately, analysts at Zacks downgraded shares of PharMerica from an “outperform” rating to a “neutral” rating in a research note on Wednesday, June 4th. They now have a $31.40 price target on the stock. Finally, analysts at Zacks upgraded shares of PharMerica from a “neutral” rating to an “outperform” rating in a research note on Tuesday, May 6th. They now have a $30.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $26.90.
PharMerica Corporation is an institutional pharmacy services company, which services healthcare facilities and provides management pharmacy services to hospitals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.